The glucagon receptor (GCGR) antagonism is a potential target for diabetes therapy but side effects such as α-cell hyperplasia and hyperglucagonemia limit therapeutic development. Here the authors report that GCGR antagonism leads to increased α-cell glucagon secretion at the single-cell level, dependent on VGF (VGF nerve growth factor inducible)
- Jianxin Jia
- Xuanxuan Bai
- Mingyu Li
